![]() ![]() Patients with longer treatment duration (at least 6 months) showed higher frequency of laboratory abnormalities than those with shorter duration. ![]() Infections and laboratory abnormalities were the most common adverse events (98 and 65 cases of 319 patients, respectively). The overall proportion of patients who achieved more than 50% hair regrowth from the baseline was 66%. We pooled 346 patients (288 receiving oral tofacitinib and 58 oral ruxolitinib) from 12 studies. Thus the authors performed a systematic review and meta-analysis. However, there have been few comprehensive reviews that have summarized treatment outcomes of Janus kinase inhibitors for alopecia areata. Recently, oral Janus kinase inhibitors, including tofacitinib and ruxolitinib, have been used off-label to treat alopecia areata. Treatment of moderate-to-severe alopecia areata is challenging as it is often refractory to conventional therapy. Clinicians should be aware of the expected efficacy, adverse events and high recurrence rate of oral JAK inhibitors for alopecia areata to effectively counsel these patients before starting therapy.Īlopecia areata is a relatively common disorder resulting in hair loss. Conclusion:īoth oral tofacitinib and ruxolitinib are effective and well tolerated in the treatment of alopecia areata. This analysis was limited by the small number of observational studies available for review, the heterogeneity of patient characteristics and the lack of long-term data. Recurrence of alopecia areata was observed within three months after discontinuation of treatment in the majority (74%) of patients. Patients treated for more than six months had a greater frequency of laboratory abnormalities as compared to those treated for shorter durations (24% vs. Subgroup analysis revealed that drug choice, mean age, sex ratio and alopecia areata subtype ratio did not significantly affect the treatment response. The overall Severity of Alopecia Tool 50 achievement rate was 66% (95% confidence interval, 54%–76%). Of the 346 patients in these 12 studies, 288 had received oral tofacitinib and 58 had received oral ruxolitinib. Results:Ī total of 1244 studies were identified of which only 12 studies met the inclusion criteria. ![]() A systematic review and meta-analysis were performed focusing on the Severity of Alopecia Tool 50 achievement rate, the frequency of adverse events and recurrence after discontinuation of treatment. Methods:Ī search of MEDLINE, Embase and Cochrane library was conducted. The aim of the study was to examine the outcome of patients with alopecia areata treated with oral tofacitinib or ruxolitinib in previously published studies. Although a number of case reports and small studies have been published, there are no comprehensive reviews examining the outcomes of using tofacitinib and ruxolitinib for the treatment of alopecia areata. Tofacitinib and ruxolitinib have been used off-label to treat alopecia areata. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |